UnitedHealth rises 1.8% after probe news and plan withdrawals coincide with market strength

What happened

UnitedHealth (UNH) rose 1.8% on October 5, 2026, as reports of a Texas probe and planned Medicare Advantage withdrawals coincided with a broadly stronger market. The S&P 500 rose 0.7% and the healthcare sector median rose 0.8% on the day. Trading volume in the stock was 1.1 times its 20-day average.

The session’s move was 1.3 times a typical daily move for the stock, suggesting the rise reflected both market and sector strength and company-specific developments.

How big was the move

The stock closed at $378.58 after opening 0.1% above the previous close and finished the five-session stretch up 0.2%. UnitedHealth’s change on the day was 1.0 percentage points better than the sector median. Over five sessions, the S&P 500 rose 1.2%, so the stock’s shorter-term performance tracked the market’s modest advance.

Market sensitivity is low: the stock has a beta of 0.44, meaning the stock tended to move less than the market. The session’s size ranked as 1.3 times a typical daily move for this name.

The technical picture

The stock sat 0.2% above its 20-day moving average and 3.6% below its 50-day moving average, while it remained 6.2% above its 200-day average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 122 consecutive trading days above the 200-day average.

Momentum measures were neutral: the Relative Strength Index (14 days) was 47, between 30 and 70. Over one month the stock fell 5.6% and over three months it fell 11.6%, while over one year it rose 7.0%, leaving it 18.0% below the 52-week high. Volatility was 21% annualized over 60 days, lower than 79% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, UnitedHealth reported revenue of $450.13 billion, which grew 6.5% from a year earlier; revenue growth one quarter earlier was growth of 9.7%. Diluted earnings per share were $15.55, with earnings per share growth from a year earlier having fallen 32.6%.

Profitability measures showed a gross margin of 22.5% (a year earlier: 20.8%) and an operating margin of 4.8% (a year earlier: 7.3%). Free-cash-flow margin was 5.2% and return on invested capital was 9.2%. The balance sheet carried net debt of 1.7 times EBITDA, and share count over one year decreased by 0.4%.

Valuation metrics showed a price to trailing earnings of 24.3 times trailing earnings and a price to forward earnings of 19.0 times expected earnings. The price to trailing earnings was lower than 57% of its own readings over the past five years (five-year median: 26.4 times earnings). Free-cash-flow yield was 7.0%.

Earnings and analyst expectations

UnitedHealth’s next report was scheduled for October 13, 2026. The last report, on July 16, 2026, delivered earnings per share of $6.38 against $4.94 expected, 29.1% above estimates. The company had beaten estimates in four consecutive quarters, with an average surprise over the last four reports of 11.5% above estimates. Historically, the typical two-day reaction after recent reports was that the stock fell 6.9%.

Analysts covering the stock numbered 52, with a consensus rating of Buy and 83% of analysts assigning a rating of Buy. The consensus price target was $473.89, which was 25.2% above the closing price.

What to watch

• October 13, 2026: next quarterly report date.
• Texas Attorney General probe: WSJ reported that Ken Paxton has opened a probe and issued civil investigative demands.
• Medicare Advantage withdrawals: UnitedHealth told regulators or planners it will withdraw from certain Medicare Advantage plans for 2027, reported by Zacks Investment Research.
• Trading flow: volume was 1.1 times its 20-day average on October 5, 2026.
• Valuation gap: consensus price target of $473.89 was 25.2% above the closing price.